INTRODUCTION
Hepatitis C virus (HCV) is an overall disease. In 2008 about 15% of the Egyptian population, aged 15-59 years had antibodies to HCV and 10% (approximately 5 million persons) had chronic HCV infection [1] . HCV transmission is continuous in Egypt, and the incidence rates have been estimated to be 2.4 per 1,000 person/ year [2] .
The incubation period for newly acquired HCV infection ranges from two weeks to six months, however, viral replication can be detected as early as one week after exposure. It has been shown that total HCV core antigen levels correlate with HCV RNA levels. Core antigen kinetics run parallel to HCV RNA kinetics during chronic HCV infection. [3] .
Diagnostic tests for hepatitis C can be divided into two general categories; serological assays that detect antibody to HCV (anti-HCV) and molecular assays that detect and/or quantify HCV RNA genomes within an infected patient. Serological assays have been subdivided into screening tests for anti-HCV, such as the enzyme immunoassay (EIA), and supplemental tests such as recombinant immunoblot assay (RIBA). Supplemental anti-HCV tests are designed to resolve false-positive testing by EIA. Detection of HCV RNA in patient specimens by polymerase chain reaction (PCR) provides evidence of active HCV infection and is potentially useful for confirming the diagnosis and monitoring antiviral response to therapy [4] .
Anti-HCV assays have several disadvantages, such as a high rate of false positivity, lack of sensitivity if used in the early window period of 45 to 68 days after infection, the inability to distinguish between acute (ongoing active, viremia), past (recovered), and persistent (chronic) infections, in addition to the possibility of false negativity with samples from immunocompromised patients, who may not have an adequate antibody response. Also, PCR analysis for measuring viral loads has some drawbacks including; expensive and requirement of technical skills [5] .
HCV core antigen (Ag) tests have been introduced to supplement anti-HCV tests or HCV PCR analysis [6, 7] . It can be identified by routine serological ELISA in specimens from the early antibody-negative phase of HCV infection. It may be a useful test for identifying window phase blood donations from antibody negative donors infected with HCV [8] . These quantitative HCV Ag assays could be used for diagnosis of HCV infection as well as for monitoring of antiviral therapy [9] . Furthermore, HCV Ag assay could also be useful in monitoring immunocompromised patients and those undergoing regular hemodialysis [10] .
The work aimed to evaluate the diagnostic performance of HCV core antigen in comparison to HCV-RNA quantification and anti-HCV-Ab analyses in blood donors.
PATIENTS AND METHODS

Study design and settings :
This comparative cross section study included ninety-two participants who attended the blood bank of Zagazig University Hospitals. Between May 2015 to November 2017. Written consents have been taken from all included participants.
Target population and sampling :
Individuals attending the blood bank of Zagazig University Hospitals. Participants were classified into two groups; group A, which Included 46 patients (32 males and 14 females) with negative HCV antibody and group B, which Included 46 patients (30 males and 16 females) with positive HCV antibody.
Exclusion criteria :
Patients who had HBV infection, history of immune-suppressive drugs, DM and any manifestations of chronic liver disease were excluded from the study.
Methods and study tools :
All participants were subjected to the following workup:  Thorough history taking and full clinical examination with special stress on manifestations of chronic liver disease.  Laboratory workup including HBsAg, HCV Ab detection by ELISA, HCV core antigen Prototype by ELISA and HCV Quantitative RNA assay.
Specimen collection and preparation:
Venous blood sample withdrawn from each participant under complete aseptic conditions using wide bore needle and slowly withdrawn from antecubital vein to avoid RBCs hemolysis. The sample was added to a sterile vacutainer dry tube, allowed to be clotted for 30 minutes, and then separated by centrifugation in PCR unit. The resulted serum was divided into 2 aliquots under strict sterile conditions and stored at -80°C to be used for HCV-Ab levels, HCV core antigen and PCR. HCV antibodies (HCV-Ab) and hepatitis B surface antigen (HBsAg) were detected by ELISA (Dia Sorin Diagnostics, Italy). This kit complements qualitative methods depended on enzyme linked immunosorbent assays (ELISA 
RESULTS
Demographic data showed non significant difference between both groups as regard gender and age (p>0.05) ( Table 1) . positive HCV core Ag in group (A) was 4 cases (8.7%) and 37 cases (80.4%) in group (B) ( Table 2) . A high significant relation between HCV AB positivity and negativity as regard HCV PCR in both groups (p<0.001) ( Table 3) . A high significant relation between HCV core antigen positivity and negativity as regard HCV PCR (p<0.001) ( Table  4) . A high significant relation between HCV core antigen positivity and HCV PCR in group A patients (p<0.001) ( Table 5) . A significant relation between HCV core antigen positivity and HCV PCR in positive HCV antibody patients and also, a statistically significant relation between HCV core antigen negativity and HCV PCR in group B patients (p<0.001) ( Table 6 ). positive HCV core Ag in 41 patients; 37 patients with positive HCV Ab and 4 patients with negative HCV ab in patients of both groups(Table7). The ability of HCV core Ag test to detect positive infected cases is 97.4% with positive predictive value of 100%, and the ability to exclude negative cases from truly negatives is 100% with negative predictive value of 70%, test accuracy is 97.8% (Table 8) . 
CONCLUSION
HCV core antigen ELISA assay is a simple and reliable direct method for detection of acute and chronic HCV infection. Since this assay is based on ELISA technology, it can be easily performed in most laboratories with low cost and this is a very important in devolving countries with low economic resources. HCV core Ag is compatible with HCV PCR, its wide application may prevent the vast majority of HCV transmissions caused by the transfusion of window phase donations. Moreover, HCV core antigen serve as a good method for direct HCV detection in patients during pre-seroconversion period 'window phase' when the antibody assays are negative. Also, it can be used for monitoring of antiviral therapy.
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